ஒப்பந்த உற்பத்தி பிரிவு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒப்பந்த உற்பத்தி பிரிவு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒப்பந்த உற்பத்தி பிரிவு Today - Breaking & Trending Today

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021
ACCESSWIRE
14 May 2021, 04:05 GMT+10
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the Company or INBP ) reports its financial results for the quarter ended March 31, 2021.
Revenue for the quarter ended March 31, 2021 was $17.1 million compared to $13.6 million for the quarter ended March 31, 2020, an increase of $3.4 million or 25.2%. The Company had operating income of $1.7 million and $1.0 million in the quarters ended March 31, 2021 and 2020, respectively.
Revenues for the nine-month period ended March 31, 2021 were $46.5 million compared to $39.2 million for the nine-month period ended March 31, 2020, an increase of $7.3 million or 18.6%. The Company had operating income for the nine-month period ended March 31, 2021 of $4.5 million compared to operating income of $2.6 million for the nine-month period ended March 31, 2020. ....

Dina Masi , Christina Kay , Riva Sheppard , Biopharma Inc , Officers Of The Company , Integrated Biopharma , Contract Manufacturing Segment , Co Chief Executive Officers , Private Securities Litigation Reform Act , Risk Factor , Annual Report , Quarterly Reports , தினா மாசி , கிறிஸ்டினா காய் , ரீவ ஷெப்பர்ட் , அதிகாரிகள் ஆஃப் தி நிறுவனம் , ஒப்பந்த உற்பத்தி பிரிவு , இணை தலைமை நிர்வாகி அதிகாரிகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆபத்து காரணி , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் ,

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021
ACCESSWIRE
14 May 2021, 04:05 GMT+10
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the Company or INBP ) reports its financial results for the quarter ended March 31, 2021.
Revenue for the quarter ended March 31, 2021 was $17.1 million compared to $13.6 million for the quarter ended March 31, 2020, an increase of $3.4 million or 25.2%. The Company had operating income of $1.7 million and $1.0 million in the quarters ended March 31, 2021 and 2020, respectively.
Revenues for the nine-month period ended March 31, 2021 were $46.5 million compared to $39.2 million for the nine-month period ended March 31, 2020, an increase of $7.3 million or 18.6%. The Company had operating income for the nine-month period ended March 31, 2021 of $4.5 million compared to operating income of $2.6 million for the nine-month period ended March 31, 2020. ....

Dina Masi , Christina Kay , Riva Sheppard , Biopharma Inc , Officers Of The Company , Integrated Biopharma , Contract Manufacturing Segment , Co Chief Executive Officers , Private Securities Litigation Reform Act , Risk Factor , Annual Report , Quarterly Reports , United States Wire Group , தினா மாசி , கிறிஸ்டினா காய் , ரீவ ஷெப்பர்ட் , அதிகாரிகள் ஆஃப் தி நிறுவனம் , ஒப்பந்த உற்பத்தி பிரிவு , இணை தலைமை நிர்வாகி அதிகாரிகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆபத்து காரணி , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் , ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு ,

Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021

Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter Ended March 31, 2021
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the Company or INBP ) reports its financial results for the quarter ended March 31, 2021.
Revenue for the quarter ended March 31, 2021 was $17.1 million compared to $13.6 million for the quarter ended March 31, 2020, an increase of $3.4 million or 25.2%. The Company had operating income of $1.7 million and $1.0 million in the quarters ended March 31, 2021 and 2020, respectively.
Revenues for the nine-month period ended March 31, 2021 were $46.5 million compared to $39.2 million for the nine-month period ended March 31, 2020, an increase of $7.3 million or 18.6%. The Company had operating income for the nine-month period ended March 31, 2021 of $4.5 million compared to operating income of $2.6 million for the nine-month period ended March 31, 2020. ....

Dina Masi , Christina Kay , Riva Sheppard , Biopharma Inc , Officers Of The Company , Integrated Biopharma , Contract Manufacturing Segment , Co Chief Executive Officers , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , தினா மாசி , கிறிஸ்டினா காய் , ரீவ ஷெப்பர்ட் , அதிகாரிகள் ஆஃப் தி நிறுவனம் , ஒப்பந்த உற்பத்தி பிரிவு , இணை தலைமை நிர்வாகி அதிகாரிகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் ,

Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter Ended December 31, 2020

Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter Ended December 31, 2020
HILLSIDE, NJ / ACCESSWIRE / February 12, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the Company or INBP ) reports its financial results for the quarter ended December 31, 2020.
Revenue for the quarter ended December 31, 2020 was $14.3 million compared to $14.2 million for the quarter ended December 31, 2019, an increase of $0.1 million or 0.7%. The Company had operating income for each of the quarters ended December 31, 2020 and 2019 of $1.2 million.
Revenues for the six-month period ended December 31, 2020 were $29.4 million compared to $25.6 million for the six-month period ended December 31, 2019, an increase of $3.8 million or 14.8%. The Company had operating income for the six-month period ended December 31, 2020 of $2.8 million compared to operating income of $1.7 million for the six-month period ended December 31, 2019. ....

Dina Masi , Christina Kay , Riva Sheppard , Biopharma Inc , Officers Of The Company , Integrated Biopharma , Contract Manufacturing Segment , Co Chief Executive Officers , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Bio Pharma , தினா மாசி , கிறிஸ்டினா காய் , ரீவ ஷெப்பர்ட் , அதிகாரிகள் ஆஃப் தி நிறுவனம் , ஒப்பந்த உற்பத்தி பிரிவு , இணை தலைமை நிர்வாகி அதிகாரிகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் , உயிர் பார்மா ,

Electronic Contract Manufacturing Market 2020 Global Leading Companies Analysis, Revenue, Trends and Forecasts 2026

Electronic Contract Manufacturing Market 2020 Global Leading Companies Analysis, Revenue, Trends and Forecasts 2026
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , South Korea , Zollner Elektronik , System Assembly Manufacturers , Sanmina Corporation Main Business , Sanmina Corporation Electronic Contract Manufacturing Production Sites , Hon Hai Foxconn Technology Group Main Business , Viasystems Group , Sanmina Corporation Electronic Contract Manufacturing Production Capacity , Research Newswire , Sanmina Corporation Electronic Contract Manufacturing Product Introduction , Kinpo Group , Assembly Manufacturers , Shenzhen Kaifa Technology , Hon Hai Foxconn Technology Group , Technology Ltd , Company Profiles , Jabil Circuit , Sanmina Corporation , See Campaign , Asteelflash Group , Kimball Electronics Group , Orient Semiconductor Electronics , Nam Tai Electronics , Contract Manufacturing Market ,